Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer

PURPOSE: Despite initial benefit from tyrosine kinase inhibitors (TKI), advanced non-small cell lung cancer (NSCLC) patients harboring ALK (ALK+) and ROS1 (ROS1+) gene fusions ultimately progress. Here we report on the potential resistance mechanisms in a series of ALK+ and ROS1+ NSCLC patients prog...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: McCoach, Caroline E., Le, Anh T., Gowan, Katherine, Jones, Kenneth, Schubert, Laura, Doak, Andrea, Estrada-Bernal, Adriana, Davies, Kurtis D., Merrick, Daniel T., Bunn, Paul A., Purcell, W. Tom, Dziadziuszko, Rafal, Varella-Garcia, Marileila, Aisner, Dara L., Camidge, D. Ross, Doebele, Robert C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6050099/
https://ncbi.nlm.nih.gov/pubmed/29636358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-2452
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados